TRCT
IOBT

Tower Research Capital (TRC)’s IO Biotech IOBT Stock Holding History

Tower Research Capital (TRC)’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-524
Closed -$2K – 6268
2022
Q2 		$2K Buy
+524
New +$3.21K ﹤0.01% 5552
2022
Q1 		– Sell
-1,572
Closed -$10K – 6308
2021
Q4 		$10K Buy
+1,572
New +$15.2K ﹤0.01% 4572

Other funds holding IOBT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Tower Research Capital (TRC)'s IOBT Position: Q3 2022 in Review

Tower Research Capital (TRC) sold out of IO Biotech (IOBT) in Q3 2022, closing a stake of 524 shares — an estimated $2K sold.

Tower Research Capital (TRC) first reported a position in IOBT in Q4 2021 and held it in 2 quarters. The position peaked at $10K in Q4 2021. 21 funds tracked by Wall St. Rank hold IOBT as of Q3 2022.

  • Tower Research Capital (TRC) reported no remaining IO Biotech position as of Q3 2022 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 524 IO Biotech shares in Q3 2022, an estimated $2K.
  • Tower Research Capital (TRC) first reported a position in IO Biotech in Q4 2021 and held it in 2 quarters.
  • Tower Research Capital (TRC)'s IO Biotech position peaked at $10K in Q4 2021.
  • 21 funds tracked by Wall St. Rank held IO Biotech as of Q3 2022.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2022, filed 10 Nov 2022.